Hypoglycemic activities of MTP-3631, a novel thiopyranopyrimidine derivative.

Abstract

MTP-3631 is a novel thiopyranopyrimidine derivative structurally different from any existent hypoglycemic agents. MTP-3631 markedly decreased basal blood glucose and improved glucose intolerance in genetically diabetic C57BL/6J ob/ob mice, which was not affected by tolbutamide. MTP-3631 also caused hypoglycemic effects in normal rats, but no change was observed in plasma insulin level. Unlike buformin, MTP-3631 did not change plasma lactate level in ob/ob mice. These results suggest that the hypoglycemic mechanism of MTP-3631 may be essentially different from those of sulfonylureas and biguanides.

• Authors: H Ogawa, Y Kunoh, T Sugiura, M Nagasaka
• Journal: Life sciences (Life Sci) Vol. 50 Issue 5 Pg. 375-81 ( 1992) ISSN: 0024-3205 [Print] Netherlands
• PMID: 1732707 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Lactates
• Piperazines
• Pyrimidines
• MTP 3631
• Tolbutamide
• Buformin

Topics

• Animals
• Blood Glucose (metabolism)
• Buformin (pharmacology)
• Glucose Tolerance Test
• Hypoglycemic Agents (pharmacology)
• Lactates (blood)
• Mice
• Mice, Obese
• Piperazines (pharmacology)
• Pyrimidines (pharmacology)
• Rats
• Rats, Inbred Strains
• Tolbutamide (pharmacology)